Short answer
Anika Therapeutics, Inc. (ANIK) filed an 8-K current report with the SEC on June 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Board-approved amendment and restatement of Anika’s 2017 Omnibus Incentive Plan.
Anika Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board-approved amendment and restatement of Anika’s 2017 Omnibus Incentive Plan
- Revised Seventh Amended Plan subject to stockholder approval at the 2026 Annual Meeting
- Terms detailed in the 2026 proxy statement and supplements filed April 28, June 1, and June 8, 2026
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 84.14% voting participation, with 11,195,667 of 13,305,624 eligible shares represented
- All three Class III nominees elected through 2029; John Henneman received 536,988 against votes
- Deloitte & Touche ratified as fiscal 2026 auditor with 11,136,590 votes for
- Executive compensation approved on advisory basis with 8,268,676 votes for
- Equity plan increased to 6,110,000 shares and ESPP capacity doubled to 400,000 shares, creating potential dilution runway
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Anika Therapeutics, Inc. 8-K filings
Get the next ANIK 8-K as it lands
Follow ANIK for push alerts, or ask the research agent what this filing means.